Health Bulletin 11/6/2022

Here are the top health stories for the day:

NMC orders crackdown on referral fee, commissions, and online procurement of patients      

With the recent release of its draft of The National Medical Commission (NMC) Professional Conduct Guidelines, the apex medical regulator has sought to issue a crackdown on the rampant practice of unethical referrals to other medical practitioners as well as diagnostic laboratories in exchange for a sum or a percentage of their fee also known as a “referral” or a “cut”

While the previous Medical Council of India ( MCI) Code of Ethics also categorized the practice of referrals as “unethical” , the NMC in its draft has linked this unethical pracitce to a quantum of punishment that can range from a 1-month suspension to a 3-month suspension.

For more details, check out the full story on the link below:

NMC Orders Crackdown On Referral Fee, Commissions, And Online Procurement Of Patients 

India records 8,329 new COVID-19 cases, 10 fatalities     

A total of 8,329 new covid cases were reported in last 24 hours in India. The authorities said despite a rise in the number of daily cases, there were no specific directions to increase the 2,000 tests on average being carried out in each of the 11 revenue districts.

Delhi recorded 655 fresh Covid-19 cases on Friday, a slight increase from 622 reported a day earlier.

Rs 103.96 Crore excess fee charged from MBBS students: Varsity, Medical College told to refund amount, pay Rs 45 lakh penalty

Taking stringent action against the practice of levying exorbitant fees, the Himachal Pradesh Private Educational Institutions Regulatory Commission (HPPERC) has imposed a penalty of Rs 45 lakh on Maharishi Markandeshwar University and Markandeshwar Medical College and Hospital. Along with the penalty, the institutes have been directed to pay around Rs 103.96 crore that they had charged as an excess fee from MBBS students studying at the medical college from the academic years 2012 to 2020.

For more details, check out the full story on the link below:

Rs 103.96 Crore Excess Fee Charged From MBBS Students: Varsity, Medical College Told To Refund Amount, Pay Rs 45 Lakh Penalty

Takeda Dengue vaccine TAK-003 provides continued protection against dengue fever through 4.5 years in trial

Takeda has announced that its dengue vaccine candidate, TAK-003, prevented 84% of hospitalized dengue cases and 61% of symptomatic cases, with no important safety risks identified, in the overall population including both seropositive and seronegative individuals through four and a half years (54 months) after vaccination in the pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial. These data were presented on June 9, 2022, at the 8th Northern European Conference on Travel Medicine (NECTM8), with plans to feature the results at additional upcoming conferences.

For more details, check out the full story on the link below:

Takeda Dengue Vaccine TAK-003 Provides Continued Protection Against Dengue Fever Through 4.5 Years In Trial  

Leave a Reply

Your email address will not be published.